Novartis acquires IFM

Novartis International AG, the Switzerland based multinational pharmaceutical corporation, has exercised an option for the acquisition of all outstanding capital stock of IFM Due, Inc., a US based biopharmaceutical company developing small-molecule, orally available drug candidates targeting aberrant inflammatory responses, from IFM Therapeutics, LLC, the US based pharmaceutical company focused on developing biological treatments for autoimmune diseases, for a total consideration of USD 835m, consisting of USD 90m in upfront payment and USD 745m in milestone payments. The strategic acquisition will grant Novartis the complete rights to IFM Due’s portfolio of STING antagonists, which address a range of serious inflammation-driven diseases.

Hive has raised EUR 12m Series A funding

Hive Computing Services SA, the Switzerland based company, that provides secure and sustainable cloud storage and computing for individuals and …

Read More →

UBS and Apollo complete carveout of former Credit Suisse business

Apollo Global Management LLC, the US based global alternative investment manager firm, has purchased USD 8b worth of senior secured …

Read More →

Svalner and Alder to merge

Svalner Skatt & Transaktion Kommanditbolag, the Sweden based independent advisory in the area of tax and financial transactions, and Alder …

Read More →

Element has raised EUR 50m

ELEMENT Insurance AG, the Germany based insurance startup offering white-label insurance products, has raised EUR 50m in a funding round …

Read More →

Marlin to complete majority growth investment in TIS

Marlin Equity Partners Limited, the UK based global private equity firm, has made a majority growth investment in TIS Treasury …

Read More →

CVC funds invest in Monbake Group

CVC Capital Partners Limited, the Luxemburg and UK based private equity firm, has acquired a 100% stake in Monbake Group, …

Read More →
close-link
close-link